Gelatinase A and B (MMP-2, MMP-9) in leukaemia MMP-2 may indicate a good prognosis in AML

Anticancer Res. 1999 Sep-Oct;19(5C):4395-400.

Abstract

We studied the expression of gelatinase-A (MMP-2) and gelatinase-B (MMP-9) in bone marrow aspirates from 54 patients with leukaemia. Specific staining patterns for different leukaemia subtypes are described. Most intresting were findings in acute myeloid leukaemia (AML), where MMP-2 staining correlated strongly with prognosis. Three year event-free survival after conventional treatment for patients with MMP-2 positive blast cells was 82%, while all the conventionally treated patients with MMP-2 negative blasts relapsed within 13.5 months. After treatment with allogeneic bone marrow transplantation, 3-year event-free survivals were 100% and 80% for MMP-2 positive and negative patients respectively.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acute Disease
  • Adult
  • Aged
  • Disease-Free Survival
  • Female
  • Humans
  • Immunoenzyme Techniques
  • Leukemia, Lymphocytic, Chronic, B-Cell / enzymology
  • Leukemia, Myeloid / enzymology*
  • Leukemia, Myeloid / genetics
  • Leukemia, Myeloid / mortality*
  • Leukemia, Myeloid / pathology
  • Male
  • Matrix Metalloproteinase 2 / biosynthesis*
  • Matrix Metalloproteinase 9 / biosynthesis*
  • Middle Aged
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma / enzymology
  • Prognosis

Substances

  • Matrix Metalloproteinase 2
  • Matrix Metalloproteinase 9